Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
Establishment Labs Holdings Inc (ESTA) provides innovative medical technologies for breast aesthetics and reconstruction. This news hub offers investors and healthcare professionals direct access to official updates, financial disclosures, and clinical advancements shaping this global medical device leader.
Key resources include: Earnings reports detailing financial performance, regulatory filings with global health authorities, and announcements of new product launches. Track developments in patented implant technologies and strategic partnerships across 40+ countries.
Bookmark this page for verified updates on surgical innovations, clinical trial results, and market expansion initiatives. Our curated news collection helps stakeholders monitor ESTA's progress in enhancing patient outcomes through advanced medical solutions.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported third quarter 2022 sales of $38.2 million, a year-over-year increase of 31.7%. Revenue guidance for 2022 has been narrowed to $158 million to $162 million, reflecting 25% to 28% growth from 2021, with foreign exchange effects expected to reduce revenue by $6.5 million. Gross profit margin improved to 68.1%, while operating expenses rose 27.5% to $36.6 million. The company holds a cash balance of $65.3 million as of September 30, 2022, and plans to commercialize Mia Femtech™ and seek FDA approval for Motiva Implants in early 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced participation in the Jefferies London Healthcare Conference and the Stephens Annual Investment Conference, both taking place from November 15-17, 2022. CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Jefferies conference on November 15 at 5:00 PM GMT, while Denhoy will speak at the Stephens conference on November 17 at 11:00 AM CT. Live webcasts and archived versions of the presentations will be available on the company's investor relations website.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q3 2022 on November 7, 2022, after market close. A conference call will be held at 4:30 pm ET to discuss these results. The company specializes in breast aesthetics and reconstruction, offering advanced silicone gel-filled implants, Motiva Implants®, with over 2 million implants distributed in over 80 countries since 2010. The company aims to continue improving women's health through innovative products.
Holzer & Holzer, LLC is investigating Establishment Labs Holdings Inc. (NASDAQ:ESTA) for potential compliance failures with federal securities laws. Following a report by Hindenburg Research, which alleged undisclosed conflicts of interest in key safety studies of Establishment Labs' breast implants, the company's stock price experienced a decline. The report claims significant pushback was received by a surgeon for publishing higher complication rates than those reported by the company. Shareholders who incurred losses are encouraged to contact Holzer & Holzer for potential legal recourse.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will host an investor event on October 5, 2022, at 4:30 p.m. ET, to discuss its innovative product, Mia Femtech®. This minimally invasive procedure aims to enhance breast aesthetics, allowing for a breast size increase of 1 to 2 cups in just 15 minutes, without general anesthesia. The company is pursuing regulatory approvals for Mia in Europe and anticipates commercialization in select markets in the first half of 2023.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, has secured Hani Zeini for a multiyear advisory role as it prepares for its US market launch. Zeini, with over 30 years in aesthetics, previously founded Sientra. His expertise will drive the company's strategy to introduce innovative breast aesthetics solutions, including the Motiva Implant product suite. With 2.0 million implants distributed globally, Establishment Labs is on track to enhance its market presence.
Establishment Labs Holdings Inc. (Nasdaq: ESTA) reported second-quarter revenues of $41.2 million, a 28.7% increase year-over-year, marking a new record. Adjusted for currency fluctuations, growth would have been 33.3%. Gross profit was 66.7% of revenue, slightly down from 67.1% in 2021. Operating expenses rose to $37.9 million, a 45% increase compared to the previous year. The company maintains its 2022 revenue guidance of $155 million to $165 million. Cash balance stood at $91.3 million as of June 30, 2022, bolstered by a new $225 million credit facility.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the completion of patient enrollment in the Motiva US IDE clinical study, which involved 827 patients across 32 centers in the US, Germany, and Sweden. The study aims to evaluate the safety and effectiveness of Motiva breast implants in various procedures. The company plans to file its PMA submission to the FDA in Q4 2023, building on this significant milestone, especially amid the challenges posed by the pandemic. The Motiva implants have been positively received in reconstructive surgery.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q2 2022 on August 8, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results. The company specializes in women's health, focusing on breast aesthetics and reconstruction, and has delivered over 2 million Motiva Implants since its launch in 2010. Their implants are known for advanced features that aim to enhance aesthetic and clinical outcomes.
FAQ
What is the current stock price of Establishment Labs Hldgs (ESTA)?
What is the market cap of Establishment Labs Hldgs (ESTA)?
